Rheumatic Fever Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: April 25, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.01 billion |
|
Revenue Forecast in 2031 |
US$ 1.50 billion |
|
CAGR |
4.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global rheumatic fever treatment market was valued at US$ 1.01 billion in 2022 and is expected to register a revenue CAGR of 4.5% to reach US$ 1.50 billion by 2031.
Rheumatic Fever Treatment Market Fundamentals
Rheumatic fever results from an untreated or inadequately treated streptococcal infection. The treatment for rheumatic fever involves a combination of antibiotics and anti-inflammatory drugs and measures to manage symptoms and prevent complications. The main goal of rheumatic fever treatment is to eliminate streptococcal infection, control inflammation, alleviate symptoms, prevent the development of rheumatic heart disease, and reduce the risk of recurrence. The specific treatment regimen will depend on the disease’s severity and the patient’s individual needs. Antibiotics are a key component of rheumatic fever treatment, particularly during the acute phase of the disease. Penicillin is the most used antibiotic for rheumatic fever treatment. It is typically administered as a long-acting injection every three to four weeks to prevent the recurrence of the infection. Erythromycin, azithromycin, and clindamycin may be used in patients with penicillin allergies or intolerance.
[5756]
Rheumatic Fever Treatment Market Dynamics
The rising prevalence of rheumatic fever in several regions, especially in low- and middle-income countries, is a major driver for the growth of the global rheumatic fever treatment market revenue. For instance, according to the WHO’s factsheet of November 2020, approximately 288,348 people die from rheumatic heart disease, with the vast majority living in low- or middle-income nations. The growing awareness about the disease and its diagnosis, coupled with better access to healthcare services, is leading to an increase in the number of patients seeking treatment for rheumatic fever, thus segmenting the global rheumatic fever treatment market revenue growth.
Additionally, increased collaboration and partnerships between healthcare providers, pharmaceutical companies, and research institutions are leading to the development of more effective and targeted treatments for rheumatic fever. Governments in several countries are taking initiatives to improve the healthcare infrastructure and increase access to healthcare services for rheumatic fever patients. This is expected to drive the demand for the rheumatic fever treatment market. Furthermore, technological advancements in the healthcare field, such as telemedicine, remote patient monitoring, and electronic health records, are expected to improve the diagnosis and management of rheumatic fever, thereby driving the demand for the global rheumatic fever treatment market.
On the other hand, the cost of treatment for rheumatic fever can be high, especially for patients in low- and middle-income countries, which can limit the demand for treatment options. Moreover, limited access to healthcare services, especially in rural and remote areas, can limit the diagnosis and treatment of rheumatic fever patients. Some treatments for rheumatic fever, such as immunosuppressive drugs, can have significant side effects, limiting their use and affecting patient compliance. Furthermore, the overuse of antibiotics has led to the development of antibiotic-resistant strains of bacteria, which can limit the effectiveness of antibiotic treatment for rheumatic fever. Additionally, the side effects of treatment and the high cost are some of the restraints impeding the overall global rheumatic fever treatment market revenue growth.
Rheumatic Fever Treatment Market Ecosystem
The global rheumatic fever treatment market is analyzed from three perspectives: drug type, distribution channel, and region.
Rheumatic Fever Treatment Market by Drug Type
[6575]
Based on the drug types, the global rheumatic fever treatment market is segmented into anti-inflammatory drugs, antibiotics, antiseizure drugs, and others.
The antibiotics segment dominated the market with the principal revenue share in 2022. Antibiotics are a key treatment option for rheumatic fever, particularly for the acute phase of the disease. Antibiotics can help to eliminate the group A streptococcal bacteria that cause the infection and prevent the development of rheumatic heart disease. The antibiotics in the rheumatic fever treatment market include a range of antibiotics, such as penicillin, erythromycin, azithromycin, and clindamycin. Penicillin is the most commonly used antibiotic for the treatment of rheumatic fever. It is typically administered as a long-acting injection every three to four weeks to prevent the recurrence of the infection. Erythromycin, azithromycin, and clindamycin may be used in patients with penicillin allergies or intolerance. These aspects contribute to the revenue growth of the antibiotics segment.
The anti-inflammatory drugs segment dominated the market with the principal revenue share in 2022. Anti-inflammatory drugs are another important treatment option for rheumatic fever, particularly for managing symptoms during the acute phase of the disease. Anti-inflammatory drugs work by reducing the inflammatory response in the body, which can help to alleviate pain, swelling, and fever. The anti-inflammatory drugs in the rheumatic fever treatment market include a range of drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. NSAIDs are the most commonly used anti-inflammatory drugs for rheumatic fever and include drugs like ibuprofen, aspirin, and naproxen. Corticosteroids, such as prednisone, may be used in patients with severe symptoms or who do not respond to NSAIDs. Colchicine may be used in patients with recurrent attacks of rheumatic fever. These aspects contribute to the revenue growth of the anti-inflammatory drugs segment.
Rheumatic Fever Treatment Market by Distribution Channel
Based on the distribution channels, the global rheumatic fever treatment market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
The hospital pharmacies segment is a key player in the rheumatic fever treatment market, with the largest revenue share in 2022. Rheumatic fever patient footfall is the highest in hospitals, as the primary diagnosis of rheumatic fever often occurs in hospitals. The hospital pharmacies are typically responsible for dispensing medications to patients, preparing and compounding drugs, managing inventory and supply chain, and ensuring medication safety and efficacy. Hospital pharmacies work closely with healthcare providers, including physicians, nurses, and pharmacists, to ensure that patients receive the appropriate medications at the right dose and time. They also play a key role in patient education and counseling, helping to ensure that patients understand their treatment regimen and can adhere to it effectively. Hospital pharmacies work closely with healthcare providers, including physicians and pharmacists, to ensure that patients receive the appropriate medications at the right dose and time. Hospital pharmacies also play a key role in patient education and counseling, helping to ensure that patients understand their treatment regimen and can adhere to it effectively. These overall factors contribute to the revenue growth of the hospital segment.
The retail pharmacies segment also dominated the market with the second largest revenue share in 2022, owing to the need for convenient access to medications and healthcare services, particularly for patients who may not have access to hospital-based pharmacies or specialty clinics. Retail pharmacies are typically prominent in low- and middle-income countries and provide prescription and over-the-counter medications to patients and a range of other health and wellness products. They provide antibiotics, anti-inflammatory drugs, and other medications to patients undergoing treatment for the disease. These overall factors contribute to the growth of the retail pharmacies segment.
Similarly, the drug demand through online pharmacies is significantly increasing due to the growing patient preference for e-commerce-based purchases for their healthcare needs. Online pharmacies offer convenience and accessibility to patients who may have difficulty accessing traditional pharmacies, such as those living in remote areas or with mobility limitations. Patients may be able to order their medications online and have them delivered directly to their homes, avoiding the need to visit a physical pharmacy. Patients may be able to order their medications online and have them delivered directly to their homes, avoiding the need to visit a brick-and-mortar pharmacy.
Rheumatic Fever Treatment Market by Region
Based on region, the global rheumatic fever treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global rheumatic fever treatment market with the largest revenue share in 2022, attributed to the presence of key market players and the rising prevalence of rheumatic fever. Additionally, companies across the region are continuously involved in partnerships and mergers acquisitions which are also expected to improve the rheumatic fever treatment market outlook.
Similarly, the Asia Pacific region is expected to be the fastest-growing geographic market during the forecast period. The Asia Pacific region is experiencing increased healthcare facilities, including hospitals, clinics, and pharmacies, where patients can receive rheumatic fever therapy. The Asia Pacific region is a significant and quickly expanding market for rheumatic fever treatment, emphasizing disease prevention, early detection, and care in children and adolescents. Other factors supporting the rapid revenue growth of the Asia Pacific rheumatic fever treatment market are the growing incidence rates, consistently increasing healthcare expenditures, and improving reimbursements.
Rheumatic Fever Treatment Market Competitive Landscape
The prominent players operating in the global rheumatic fever treatment market are:
Rheumatic Fever Treatment Market Strategic Developments
Rheumatic fever is a disease that results from an untreated or inadequately treated streptococcal infection.
The global rheumatic fever treatment market was valued at US$ 1.01 billion in 2022.
The expected size of the global rheumatic fever treatment market in 2031 is US$ 1.50 billion.
The expected revenue CAGR of the rheumatic fever treatment market during the forecast period is 4.5% from 2023 to 2031.
Some prominent players operating in the global rheumatic fever treatment market are Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Lupin Limited.
*Insights on financial performance are subject to the availability of information in the public domain